Defendant
1 case as defendant.
AstraZeneca Pharmaceuticals LP is the United States division of AstraZeneca plc, a Swedish-British multinational pharmaceutical and biotechnology company. The parent company, AstraZeneca plc, was formed in 1999 through the merger of Sweden's Astra AB and the UK's Zeneca Group PLC. Headquartered in Cambridge, UK, AstraZeneca plc is a publicly traded company listed on the London Stock Exchange, Nasdaq Stockholm, and the New York Stock Exchange. As of 2025, AstraZeneca plc reported total revenue of approximately $58.7 billion and employed around 89,900 people globally. Its market capitalization was approximately $292 billion as of July 2026.
The company focuses on the research, development, and commercialization of prescription medicines across key therapeutic areas. These include oncology, rare diseases, and biopharmaceuticals, encompassing cardiovascular, renal & metabolism, and respiratory & immunology. Notable products include Tagrisso for lung cancer and CALQUENCE® (acalabrutinib) for chronic lymphocytic leukemia and mantle cell lymphoma.
AstraZeneca Pharmaceuticals LP's patent litigation posture, based on the provided data, is that of an operating company defending its products. The company has been named as a defendant in one tracked case and has no recorded plaintiff cases.
The sole tracked case, Wyeth LLC v. AstraZeneca Pharmaceuticals LP, occurred in the U.S. Court of Appeals for the Federal Circuit in 2024. This case involved claims by Wyeth, a subsidiary of Pfizer, that AstraZeneca's lung cancer treatment, Tagrisso, infringed on its patents. A U.S. appeals court recently confirmed a decision in favor of AstraZeneca, deeming the patents in question invalid.
The U.S. Court of Appeals for the Federal Circuit affirmed a district court's ruling, finding claims of US Patent 10596162 and US 10603314 invalid for lack of enablement, thereby overturning a $107.5 million jury verdict Wyeth had won against AstraZeneca in Delaware.